List of Clindesse drug patents

Clindesse is owned by Padagis Us.

Clindesse contains Clindamycin Phosphate.

Clindesse has a total of 2 drug patents out of which 0 drug patents have expired.

Clindesse was authorised for market use on 30 November, 2004.

Clindesse is available in cream;vaginal dosage forms.

Clindesse can be used as method of treating bacterial vaginosis.

The generics of Clindesse are possible to be released after 02 December, 2026.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6899890 PADAGIS US Bioadhesive drug delivery system
Apr, 2023

(2 months from now)

US9789057 PADAGIS US Pharmaceutical delivery system
Dec, 2026

(3 years from now)

Drugs and Companies using CLINDAMYCIN PHOSPHATE ingredient

Market Authorisation Date: 30 November, 2004

Treatment: Method of treating bacterial vaginosis

Dosage: CREAM;VAGINAL

How can I launch a generic of CLINDESSE before it's patent expiration?
More Information on Dosage

CLINDESSE family patents

11

United States

5

China

4

Australia

3

Korea, Republic of

3

Brazil

3

Japan

3

Argentina

3

Canada

3

European Union

1

Malaysia

1

Italy

1

Mexico

1

Hungary

1

South Africa

1

Portugal

1

Russia

1

Peru

1

Singapore

1

EA

1

France

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in